Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Spironolactone-induced agranulocytosis

A M Whitling1, P E Pérgola, J L Sang

  • 1Clinical Pharmacy Programs, College of Pharmacy, University of Texas at Austin, USA.

The Annals of Pharmacotherapy
|May 1, 1997
PubMed
Summary

Spironolactone can cause agranulocytosis, a serious condition where the body lacks infection-fighting white blood cells. Early detection and stopping the drug are crucial for patient recovery.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial.

Lancet (London, England)·2013
Same author

Albuminuria and the risk of incident stroke and stroke types in older adults.

Neurology·2010
Same author

Bioactive nitric oxide concentration does not increase during reactive hyperemia in human skin.

Journal of applied physiology (Bethesda, Md. : 1985)·2004
Same author

[Effects of inhibition of PKC alpha on breast cancer cell phenotype and expressions of cyclin E and CDK2].

Shi yan sheng wu xue bao·2003
Same author

Bradykinin does not mediate cutaneous active vasodilation during heat stress in humans.

Journal of applied physiology (Bethesda, Md. : 1985)·2002
Same author

Antiplatelet therapy in secondary stroke prevention.

Expert opinion on pharmacotherapy·2002

Area of Science:

  • Pharmacology
  • Hematology
  • Hepatology

Background:

  • Spironolactone is a medication used for conditions like heart failure and high blood pressure.
  • Drug-induced agranulocytosis is a rare but severe adverse effect.
  • Cryptogenic liver disease presents unique challenges in medication management.

Observation:

  • A case of agranulocytosis was observed in a patient with cryptogenic cirrhosis treated with spironolactone.
  • Leukocyte and absolute neutrophil counts dropped significantly after spironolactone initiation.
  • Bone marrow biopsies indicated a toxic effect of spironolactone on myeloid precursors.

Findings:

  • Spironolactone was identified as the cause of agranulocytosis in this patient.
  • Agranulocytosis resolved within five days of discontinuing spironolactone.
  • The incidence of drug-induced agranulocytosis is approximately 6.2 cases per million persons annually.

Implications:

  • Patients with risk factors such as age, hepatic/renal impairment, or concurrent medications may be at higher risk.
  • Close monitoring for agranulocytosis is recommended in patients taking spironolactone.
  • Early recognition and drug cessation can significantly improve patient outcomes.

Related Experiment Videos